Business Context and Reporting Period
Harmony Biosciences Holdings, Inc. furnished this Form 8-K on August 10, 2021, under Items 2.02 and 7.01. The disclosure relates to the company’s financial results for the quarter ended June 30, 2021, including an earnings conference call and an investor presentation.
Financial Results and Key Metrics
The filing text provided does not include clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. Those details may be contained in the referenced conference-call transcript, investor presentation, or the company’s Form 10-Q for the quarter ended June 30, 2021, but they are not included in the supplied text.
Material Changes Versus Prior Comparable Period
The supplied Form 8-K text does not quantify or describe specific changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- The company furnished an investor presentation dated August 10, 2021 and stated that it may use the presentation, in whole or in part, in communications with investors and analysts.
- The presentation and related statements may contain forward-looking statements based on management’s current expectations, plans, assumptions, and projections.
- Risks include the factors described in the company’s 2020 Form 10-K, its June 30, 2021 Form 10-Q, and other SEC filings. The filing does not provide specific guidance figures or quantify individual risks.
- Exhibits 99.1 and 99.2 were furnished rather than filed and generally are not subject to Section 18 liability or incorporated by reference unless specifically stated otherwise.
Important Facts for Investors to Verify
- Review the June 30, 2021 Form 10-Q for complete financial statements, liquidity, debt, cash-flow, and operating metrics.
- Review Exhibit 99.1 for management’s discussion of quarterly results, operating trends, and outlook.
- Review Exhibit 99.2 for investor-presentation data, product or commercial updates, and any quantitative guidance.
- Assess the forward-looking statements against the risk factors in the company’s Form 10-K and Form 10-Q.